Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Vertex
More »

  • Creative Acquisition in Biotech, Take Two
    ... Biogen Idec, Celgene, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Alexion Pharmaceuticals, Cubist Pharmaceuticals, United Therapeutics, and Biomarin Pharmaceutical. ...
    8-1-2013
  • Vertex CF Drug Shows Promise for a New Set of Patients in Phase...
    Vertex Pharmaceuticals has released promising Phase III results for people with cystic ... Vertex also said that administration of ivacaftor resulted in improved weight gain and ...
    7-30-2013
  • Novo Nordisk Tops GEN List of Top 25 Biotech Companies
    Isis Pharmaceuticals (NASDAQ:ISIS), Onyx Pharmaceuticals (NASDAQ:ONXX), Vertex Pharmaceuticals (NASDAQ:VRTX), and especially Gilead, which nearly tripled its market cap. ...
    7-25-2013
  • Top 25 Biotech Companies of 2013
    Pharmaceuticals, Onxy Pharmaceuticals, Vertex Pharmaceuticals, and especially Gilead ... 56.4% Position on 2012 List: #14 #12. Vertex Pharmaceuticals 2013 Market Cap: $17.495 ...
    7-15-2013
  • People in the News
    ... Eric R. Olson, Ph.D. Eric R. Olson, Ph.D. , joined Syros Pharmaceuticals as CSO. Formerly, Dr. Olson was research vp for respiratory diseases at Vertex Pharmaceuticals. ...
    7-10-2013
  • GEN | Biolinks
    ... of Economic Development Vermont Economic Development Authority Versartis Verseon Vertex Pharmaceuticals Virginia Economic Development Partnership VirginiaBIO Vitae ...
  • BMS Shores Up R&D after Trial Failure, Plavix Patent Loss
    ... Cuss as CSO, BMS announced a pair of key R&D moves. On Friday, BMS and Vertex Pharmaceuticals said they will team up to conduct Phase II studies of a once-daily combination therapy ...
    4-8-2013
  • BMS, Vertex Plan Phase II Studies of Hep C Combo Therapy
    Bristol-Myers Squibb and Vertex said today they will team up to conduct Phase II studies ... with BMS, Vertex said it plans to conduct two Phase II studies of the combination. ...
    4-5-2013
  • Top 20 Best-Selling Drugs Approved and Launched During 2012
    ... August 31, 2012 #1. Kalydeco(tm) (ivacaftor) 2012 sales: $171.6 million Marketer(s): Vertex Pharmaceuticals Indication(s): Cystic fibrosis (CF) in patients 6 years old and older ...
    4-4-2013
  • Small Firms Look Optimistically to Future
    At Vertex, "We're sharpening our focus for the future to create transformative medicine for specialty markets-not drugs that are merely wanted, but drugs that are needed to ...
    3-1-2013
  • CF GeneE
    Designed by Vertex Pharmaceuticals, CF GeneE provides animations and videos illustrating the effects of common mutations in the CFTR (cystic fibrosis transmembrane conductance ...
    2-1-2013
  • Getting FDA to Yes
    ... & Johnson's Janssen Therapeutics unit; and Vertex Pharmaceuticals' Kalydeco (ivacaftor) for cystic fibrosis with the G551D mutation in the CFTR gene, the first CFTR potentiator. ...
    1-8-2013
  • Biotech: A Model of Creative Acquisition
    ... companies that were among the top ten for 2011 but not for 2005. Those six companies-Vertex, Alexion, Cubist, United Therapeutics, Amylin, and ViroPharma-reported total revenues ...
    12-1-2012
  • CF Foundation Commits $58M to Pfizer Partnership
    The foundation has successfully collaborated with other drug developers. With Vertex Pharmaceuticals, the foundation persuaded FDA in January to approve ivacaftor (Kalydeco), the ...
    11-19-2012
  • Vertex Tests Oral HCV Combos with Janssen and GSK
    Vertex Pharmaceuticals announced separate non-exclusive collaborations with Janssen ... chronic, non-cirrhotic genotype 1 HCV. Vertex and Janssen will share associated costs. ...
    11-1-2012
  • More »

    Journal Articles

  • An Interview with Jesús "Tito" González, Ph.D., Senior Director...

    ASSAY and Drug Development Technologies
    An Interview with Jesús "Tito" González, Ph.D., Senior Director, Biology, Vertex Pharmaceuticals, San Diego, CA ASSAY and Drug Development Technologies
  • Optimally Orienting Physical Networks
    Dana Silverbush, Michael Elberfeld, Roded Sharan
    Journal of Computational Biology
    In a network orientation problem one is given a mixed graph, consisting of directed and undirected edges, and a set of source-target vertex pairs. The goal is to orient the ...
  • Reductions of Thalamic Volume and Regional Shape Changes in the...
    Davinia Fernández-Espejo, Carme Junque, Montserrat Bernabeu, Teresa Roig-Rovira, Pere Vendrell, Jose M. Mercader
    Journal of Neurotrauma
    clinical variables were performed for the total thalamic volume and for each surface vertex. Total thalamic volume was significantly lower in patients than in healthy volunteers. ...
  • Preoperative Stereotactic Body Radiotherapy to a Skull Renal...
    Gunita Mitera, Georg A. Bjarnason, Farhad Pirouzmand, Juan Bilbao, Cyril Danjoux, Arjun Sahgal
    Journal of Palliative Medicine
    Case presentation: A 58-year-old woman presented with an asymptomatic large 7-cm tumor on the parieto-occipital vertex of the skull. Given the location of this lesion along with ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll